Who Paid My Doc
Aaron Mansfield
Medical Oncology Rochester, MN Medical Doctor
NPI 1437278959 CMS profile 403976
200 1St St Sw, Rochester, MN 55905
General payments
$48,408
Research payments
$30,334
Ownership & investment interest
$0
Research they led as principal investigator
$5,011,976
Through program year 2025, Aaron Mansfield of Rochester, MN is reported in the CMS Open Payments database as having received $48,408 across 35 general payments and $30,334 in research payments paid to them. Separately, studies naming them as principal investigator received $5,011,976 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 87th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,366 | 3 | |
| 2024 | General | $3,997 | 4 | |
| 2023 | General | $5,760 | 2 | |
| 2023 | Research | $1,752 | 4 | |
| 2022 | General | $4,086 | 3 | |
| 2021 | General | $8,640 | 6 | |
| 2021 | Research | $21,407 | 2 | |
| 2020 | General | $6,830 | 4 | |
| 2020 | Research | $7,175 | 8 | |
| 2019 | General | $13,729 | 13 |
Beside peers
- Aaron Mansfield
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Aaron Mansfield were reported at $5,366. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Aaron Mansfield | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13,729 | $968 | $140–$6,658 | $163 |
| 2020 | $6,830 | $747 | $102–$5,891 | $114 |
| 2021 | $8,640 | $430 | $50–$4,098 | $132 |
| 2022 | $4,086 | $812 | $127–$4,907 | $149 |
| 2023 | $5,760 | $957 | $144–$5,248 | $160 |
| 2024 | $3,997 | $1,042 | $149–$5,650 | $164 |
| 2025 | $5,366 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
113
Drug cost
$1,090,047
Branded share of claims
58.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | Brand | 32 | $505,505 | |
| Lorbrena Lorlatinib | Brand | 18 | $314,194 | |
| Alecensa Alectinib Hcl | Brand | 16 | $269,930 | |
| Dexamethasone | Generic | 31 | $266 | |
| Olanzapine | Generic | 16 | $152 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 121 billing codesPaid by Medicare
$1,383,578
Medicare patients
265
Services billed
56,811
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 67% | |
| Cancer | 53% | |
| Arthritis | 32% | |
| Chronic kidney disease | 30% | |
| Ischemic heart disease | 27% | |
| Diabetes | 25% | |
| Atrial fibrillation | 23% | |
| Heart failure | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 31 | 7,802 | $328,807 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 25 | 7,380 | $285,739 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 27 | 4,800 | $522 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 50 | 570 | $478 |
| Injection, fluorouracil, 500 mg J9190 | Office | 17 | 156 | $376 |
| Injection, carboplatin, 50 mg J9045 | Office | 14 | 98 | $283 |
| Injection, paclitaxel, 1 mg J9267 | Office | 15 | 2,268 | $183 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 16 | 38 | $143 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 56 | 802 | $73 |
| Infusion, normal saline solution , 1000 cc J7030 | Office | 12 | 15 | $31 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
49 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Medical Oncology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.